Interleukin-1 Regulates Multiple Atherogenic Mechanisms in Response to Fat Feeding
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Atherosclerosis is an inflammatory process that develops in individuals with known risk factors that include hypertension and hyperlipidaemia, influenced by diet. However, the interplay between diet, inflammatory mechanisms and vascular risk factors requires further research. We hypothesised that interleukin-1 (IL-1) signaling in the vessel wall would raise arterial blood pressure and promote atheroma. METHODOLOGY/PRINCIPAL FINDINGS: Apoe(-/-) and Apoe(-/-)/IL-1R1(-/-) mice were fed high fat diets for 8 weeks, and their blood pressure and atherosclerosis development measured. Apoe(-/-)/IL-R1(-/-) mice had a reduced blood pressure and significantly less atheroma than Apoe(-/-) mice. Selective loss of IL-1 signaling in the vessel wall by bone marrow transplantation also reduced plaque burden (p < 0.05). This was associated with an IL-1 mediated loss of endothelium-dependent relaxation and an increase in vessel wall Nox 4. Inhibition of IL-1 restored endothelium-dependent vasodilatation and reduced levels of arterial oxidative stress. CONCLUSIONS/SIGNIFICANCE: The IL-1 cytokine system links atherogenic environmental stimuli with arterial inflammation, oxidative stress, increased blood pressure and atherosclerosis. This is the first demonstration that inhibition of a single cytokine can block the rise in blood pressure in response to an environmental stimulus. IL-1 inhibition may have profound beneficial effects on atherogenesis in man.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
Bedard, K., & Krause, K.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00044.2005 · Cited by 6,989
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Appel, L. J., Sacks, F. M., Carey, V. J., Obarzanek, E., Swain, J. F., Miller, E. R., Conlin, P. R., Erlinger, T. P., Rosner, B. A., Laranjo, N. M., et al. (2005) · JAMA · doi:10.1001/jama.294.19.2455 · Cited by 1,170
Dickinson, H. O., Mason, J. M., Nicolson, D. J., Campbell, F., Beyer, F. R., Cook, J. V., Williams, B., & Ford, G. A. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000199800.72563.26 · Cited by 759
Lack of Interleukin-1β Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice
Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., Asano, M., Moriwaki, H., & Seishima, M. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000064374.15232.c3 · Cited by 748 · cited 1×
“, and inhibition of IL-1 in animal models is associated with reduced amounts of atheroma”
BackgroundLaursen, J. B., Somers, M., Kurz, S., McCann, L., Warnholtz, A., Freeman, B. A., Tarpey, M., Fukai, T., & Harrison, D. G. (2001) · Circulation · doi:10.1161/01.cir.103.9.1282 · Cited by 721 · cited 1×
“Levels of ROS in aortic tissue were determined by chemiluminescent assay [22].”
MethodCoronary Artery Superoxide Production and Nox Isoform Expression in Human Coronary Artery Disease
Guzik, T. J., Sadowski, J., Guzik, B., Jopek, A., Kapelak, B., Przybyłowski, P., Wierzbicki, K., Korbut, R., Harrison, D. G., & Channon, K. M. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000196651.64776.51 · Cited by 278
The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle
ELLMARK, S., DUSTING, G., NGTANGFUI, M., GUZZOPERNELL, N., & DRUMMOND, G. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.10.026 · Cited by 213
Alp, N. J., McAteer, M. A., Khoo, J., Choudhury, R. P., & Channon, K. M. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000115637.48689.77 · Cited by 194 · cited 1×
“Superoxide production in mouse aortic tissue sections was detected in-situ [21].”
BackgroundSelf-citation
Cited by
The IL-1 family: regulators of immunity
Sims, J. E., & Smith, D. E. (2010) · Nature Reviews Immunology · doi:10.1038/nri2691 · Cited by 1,418
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation
Marchio, P., Guerra-Ojeda, S., Vila, J. M., Aldasoro, M., Victor, V. M., & Mauricio, M. D. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8563845 · Cited by 621
Interleukin 1α and the inflammatory process
Di Paolo, N. C., & Shayakhmetov, D. M. (2016) · Nature Immunology · doi:10.1038/ni.3503 · Cited by 568
“Although the development of atherosclerotic lesions has an important IL-1R1 signaling component 79 , evidence indicates that macrophage-derived IL-1 α is a principal cytokine controlling the development of atherosclerotic plaques 26 .”
Kim, S. R., Lee, S.-G., Kim, S. H., Kim, J. H., Choi, E., Cho, W., Rim, J. H., Hwang, I., Lee, C. J., Lee, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15983-6 · Cited by 536
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets
Ramji, D. P., & Davies, T. S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.04.003 · Cited by 469
Molecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 459
Morton, A. C., Rothman, A. M. K., Greenwood, J. P., Gunn, J., Chase, A., Clarke, B., Hall, A. S., Fox, K., Foley, C., Banya, W., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu272 · Cited by 353
Self-citationFunction and regulation of IL‐1α in inflammatory diseases and cancer
Malik, A., & Kanneganti, T. (2018) · Immunological Reviews · doi:10.1111/imr.12615 · Cited by 327
Freigang, S., Ampenberger, F., Weiss, A., Kanneganti, T.-D., Iwakura, Y., Hersberger, M., & Kopf, M. (2013) · Nature Immunology · doi:10.1038/ni.2704 · Cited by 307
Targeting Interleukin-1 in Heart Disease
Van Tassell, B. W., Toldo, S., Mezzaroma, E., & Abbate, A. (2013) · Circulation · doi:10.1161/circulationaha.113.003199 · Cited by 302
Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles
Bonora, M., Wieckowski, M. R., Sinclair, D. A., Kroemer, G., Pinton, P., & Galluzzi, L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0074-0 · Cited by 294
NLRP3 at the interface of metabolism and inflammation
Haneklaus, M., & O'Neill, L. A. J. (2015) · Immunological Reviews · doi:10.1111/imr.12285 · Cited by 294
Gardner, S. E., Humphry, M., Bennett, M. R., & Clarke, M. C. H. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305896 · Cited by 285
Hubackova, S., Krejcikova, K., Bartek, J., & Hodny, Z. (2012) · Aging · doi:10.18632/aging.100520 · Cited by 272
Kones, R. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 259
Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice
Gomez, D., Baylis, R. A., Durgin, B. G., Newman, A. A. C., Alencar, G. F., Mahan, S., St. Hilaire, C., Müller, W., Waisman, A., Francis, S. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0124-5 · Cited by 256
Self-citationZheng, Y., Humphry, M., Maguire, J. J., Bennett, M. R., & Clarke, M. C. H. (2013) · Immunity · doi:10.1016/j.immuni.2013.01.008 · Cited by 205
“Finally, atherosclerosis is highly dependent on IL-1 (Chamberlain et al., 2009; Chi et al., 2004; Duewell et al., 2010), although recent work casts doubt on IL-1b’s role (Menu et al.”
Inflammation: a culprit for vascular calcification in atherosclerosis and diabetes
Bessueille, L., & Magne, D. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1876-4 · Cited by 172
“In mouse, IL-1 receptor I deficiency [102], as well as overexpression of the IL-1 receptor antagonist IL-1Ra [103, 104], lead to less atherosclerosis.”
BackgroundA Role for TRPV1 in Influencing the Onset of Cardiovascular Disease in Obesity
Marshall, N. J., Liang, L., Bodkin, J., Dessapt-Baradez, C., Nandi, M., Collot-Teixeira, S., Smillie, S.-J., Lalgi, K., Fernandes, E. S., Gnudi, L., et al. (2013) · Hypertension · doi:10.1161/hypertensionaha.112.201434 · Cited by 95
“Both IL-1β and IL-6 have also been linked to hypertension and, in the case of IL-6, T-cell activation and insulin resistance.(33,34) These collected findings suggest a need to learn more about the interplay between the different facets of the metabolic syndrome and the factors that lead to the onset of hypertension.”
BackgroundDicer Knockdown Inhibits Endothelial Cell Tumor Growth via MicroRNA 21a-3p Targeting of Nox-4
Gordillo, G. M., Biswas, A., Khanna, S., Pan, X., Sinha, M., Roy, S., & Sen, C. K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.519264 · Cited by 44
Metadata
- Authors
- Chamberlain, J., Francis, S., Brookes, Z., Shaw, G., Graham, D., Alp, N. J., Dower, S., & Crossman, D. C.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-04-06
- Volume
- 4
- Issue
- 4
- Pages
- e5073
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2017241556
- Cited by
- 114
- References
- 9
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.